As similar result to tumour volume, the Bev + anti-CD47 treatment formulation demonstrated smaller tumour weight, especially in the Bev (10 mg/kg) + anti-CD47 (20 mg/kg) group (0.26 ± 0.05 g), whereas the tumour weight in the Bev group (0.58 ± 0.20 g) and anti-CD47 group (0.85 ± 0.24 g) were smaller than those in the tumour PBS group (1.15 ± 0.22 g). This evidence concerns the gene CD47 and neoplasm.